PURPOSE: To determine if increasing the biologically equivalent dose (BED) via various radiation fractionation regimens is correlated with clinical outcomes or toxicities for prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS AND MATERIALS: We performed a meta-analysis that included 12,756 prostate cancer patients from 55 studies published from 2003 to 2013 who were treated with non-dose-escalated conventionally fractionated external beam radiation therapy (non-DE-CFRT), DE-CFRT, hypofractionated RT, and high dose rate brachytherapy (HDR-BT; either mono or boost) with ⩾5-year actuarial follow-up. BEDs were calculated based on the following formula: (nd[1+d/(α/β)]), where n is the number of fractions, and d is dose per fraction; assuming an α/β of 1.5 for prostate cancer and 3.0 for late toxicities. Mixed effects meta-regression models were used to estimate weighted linear relationships between BED and the observed percentages of patients experiencing late toxicities or 5-year freedom from biochemical failure (FFBF).
RESULTS: Increases in 10Gy increments in BED (at α/β of 1.5) from 140 to 200Gy were associated with 5-unit improvements in percent FFBF. Dose escalation of BED above 200Gy was not correlated with FFBF. Increasing BED (at α/β of 3.0) from 98 to 133Gy was associated with increased gastrointestinal toxicity. Dose escalation above 133Gy was not correlated with toxicity.
CONCLUSIONS: An increase in the BED to 200Gy (at α/β of 1.5) was associated with increased disease control. Doses above 200Gy did not result in additional clinical benefit.
Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. Are you the author?
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; Department of Radiation Oncology, Sidney Kimmel Cancer Center at Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA; Department of Radiation Oncology, Sidney Kimmel Cancer Center at Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA; Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Reference: Radiother Oncol. 2015 May 28. pii: S0167-8140(15)00246-7.